利水消鼓贴脐疗治疗肝硬化腹水的随机对照试验方案
本研究为双盲随机平行安慰剂对照试验,计划招募82例肝硬化腹水患者,按1:1随机分为治疗组和安慰剂组,评估利水消鼓贴脐疗联合红光的疗效与安全性。主要疗效指标为腹水深度,次要指标包括腹围、体重、尿量、中医症状评分及慢性肝病问卷,并报告不良事件。
要点
- 利水消鼓贴脐疗联合红光治疗肝硬化腹水,每日一次,最长10天,随访30天。
- 主要疗效指标为腹水深度,次要指标含腹围、体重、尿量、中医症状评分及CLDQ。
- 该试验为首次严谨评估利水消鼓贴脐疗疗效与安全性的随机对照研究。
核心结论
- 该随机试验将首次严谨评估利水消鼓贴脐疗治疗肝硬化腹水的疗效与安全性。
研究设计与样本
- 双盲、随机、平行、安慰剂对照试验,计划招募82例肝硬化腹水患者,按1:1随机分组。
关键数值与推荐
- 治疗组接受利水消鼓贴脐疗加红光照射及常规治疗,安慰剂组接受安慰剂贴脐疗加红光照射及常规治疗。
- 两组干预均为每日一次,最长10天,末次治疗后随访30天。
- 主要疗效指标为腹水深度,次要指标包括腹围、体重、尿量、中医症状评分及慢性肝病问卷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ascites is one of the most common complications of cirrhosis. Umbilical therapy with traditional Chinese medicines has been increasingly prescribed to treat cirrhotic ascites. However, high-quality evidence from clinical trials supporting such application of traditional Chinese medicines remains limited. Therefore, we designed a clinical trial to evaluate the efficacy and safety of umbilical therapy with the Lishui Xiaogu cataplasm formulation applied to treat cirrhotic ascites. METHODS/DESIGN: This ongoing study is a double-blind, randomized, parallel, placebo-controlled trial. A total of 82 patients will be recruited and randomly assigned to either a treatment group or a placebo group, in a 1:1 ratio. The treatment group will receive umbilical therapy with the Lishui Xiaogu cataplasm plus red light irradiation along with conventional treatment; the placebo group will receive umbilical therapy with a placebo cataplasm plus red light irradiation along with conventional treatment. Interventions for both groups will be administered once daily for up to 10 days, with a 30-day follow-up after the last treatment. The primary efficacy measurement will be ascites depth. Secondary efficacy measurements will include abdominal perimeter, weight, urine volume, the symptomatic score of traditional Chinese medicine, and the Chronic Liver Disease Questionnaire. Adverse events will also be reported. DISCUSSION: This randomized trial will be the first rigorous study designed to evaluate the efficacy and safety of umbilical therapy with Lishui Xiaogu cataplasm applied for cirrhotic ascites. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-INR-16007686 . Registered on 1 January 2016.
引用
- Yang X, Ru S, Luo L, et al. Efficacy and safety of umbilical therapy with the traditional Chinese medicine formulation Lishui Xiaogu cataplasm for cirrhotic ascites: protocol for a randomized controlled trial. Trials. 2019. PMID: 30760320. doi:10.1186/s13063-019-3221-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。